Phoenix Bio

NEWS

NEWS

LATEST INFORMATION

February 26, 2021

Rare Disease Day: OTCD is a Rare Disease

February 22, 2021

Human hepatocytes – PXB-cells® – 2020. Part II

In our previous post we summarized 2020 publications where PXB-cells® were used in lipid metabolism, drug metabolism and hepatitis B studies. Here we bring to your attention five 2020 publications which discuss the use of PXB-cells® in toxicity-related applications (in 2D and in 3D formats).

February 18, 2021

Human hepatocytes – PXB-cells® – 2020. Part I

Here we summarize 2020 publications where PXB-cells® were used in such application areas as lipid metabolism, drug metabolism and hepatitis B. In Part II we will review 2020 publications where PXB-cells® were used in toxicity-related applications.

February 11, 2021

PXB-cells®: Robust Human Hepatocytes

February 04, 2021

Non-alcoholic fatty liver-like properties of PXB-cells

February 4, 2021

The recently published Letter to Editor (“PXB-cells, fresh primary hepatocytes from humanized mouse livers, exhibit nonalcoholic fatty liver like properties, including large very low-density lipoproteins”, J. Biol. Micromol., 2021; 21 (1), 51-52) investigated intra- and extracellular lipid levels and lipoprotein profiles in PXB-cells® isolated at several time points post-transplantation of human hepatocytes into the PXB-mouse®. Numerous large lipid droplets were found in PXB-cells isolated 16- and 19-weeks post-transplantion of human hepatocytes into PXB-mice. This may occur due to a deficiency in circulating human growth factor in the PXB-Mouse®, as was previously described in “Growth Hormone-Dependent Pathogenesis of Human Hepatic Steatosis in a Novel Mouse Model Bearing a Human Hepatocyte-Repopulated Liver” by Dr. C. Tateno and her team (Endocrinology, 2011; 152: 1479-1491).

January 27, 2021

In vivo OTCD mouse model

January 27, 2021

In vivo OTCD mouse model from PhoenixBio and in vitro model of OTCD based on hepatocytes isolated from those mice were developed by our R&D team.

Serial transplantation (TP) to achieve high repopulation of mouse liver with donor hepatocytes

Serial transplantation (TP) to achieve high repopulation of mouse liver with donor hepatocytes

Our recent Open Access paper “Humanized liver mouse model with transplanted human hepatocytes from patients with ornithine transcarbamylase deficiency” describes the development of a mouse model containing OTC-deficient hepatocytes with the characteristics similar to OTCD patients and in vitro model of OTCD based on hepatocytes isolated from those mice. Ornithine transcarbamylase deficiency (OTCD) is a metabolic and genetic disease which results in the dysfunction of the urea cycle. Primary human hepatocytes isolated from male and female pediatric patients were used for the xenotransplantation into cDNA-uPA/SCID mice to develop this mouse model containing OTC-deficient hepatocytes.

Serial transplantation was used to achieve high repopulation of the mouse liver with donor hepatocytes (Replacement Index of over 80%) from OTC deficient patients. Highly humanized OTCD mice exhibited similar characteristics seen in OTCD patients including increased blood ammonia levels and urine orotic acid levels enhanced by allopurinol.

December 17, 2020

Results from Studies using PXB-mouse and PXB-cells being presented at AASLD 2020

September 04, 2020

Results from Studies using PXB-mouse and PXB-cells being presented at EASL 2020